Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus
Main finding · COVID-19 incidenceResult — go to the resultAdjusted hazard ratio 1.02 95% CI 0.94–1.10Authors' conclusion
The present study showed that metformin use before COVID-19 vaccination could not reduce COVID-19 incidence; however, it was associated with significantly lower risks of hospitalization, intensive care service, mechanical ventilation, and mortality in fully vaccinated type 2 diabetes mellitus patients.
Study context
- Population
- Patients with T2D fully vaccinated against COVID-19 between January 1, 2020, and November 22, 2022, US TriNetX network
- Participants
- 123,709 patients20,894 matched pairs
- Exposure
- Metformin use before COVID-19 vaccination vs no metformin
- Metformin usersn = 20,894
- Nonusersn = 20,894reference
- Outcome
- COVID-19 infection
Methodological detailspropensity-score matched, TriNetX US collaborative network
- Propensity-score matched
- TriNetX US collaborative network
Main finding
COVID-19 incidence
Adjusted hazard ratio
1.02
95% CI 0.94–1.10
Metformin usersvs Nonusers
aHR 1.02 (95% CI 0.94–1.10)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Hospitalization | 0.85 (0.81–0.89) | |
| Critical care services | 0.81 (0.70–0.94) | |
| Mechanical ventilation | 0.75 (0.60–0.95) | |
| All-cause mortality | 0.75 (0.63–0.89) | |
| 0.512Adjusted hazard ratio (log scale) |
Subgroup and sensitivity analyses
- The subgroup analyses and sensitivity analysis showed similar results
Original publication
Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. Published 6 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →